Skip to main content
. 2019 Apr 22;104(9):3757–3767. doi: 10.1210/jc.2019-00153

Figure 2.

Figure 2.

Definition of time-variant oral glucocorticoid exposure variables. Inclusion criteria included a diagnosis of inflammatory bowel disease, systemic lupus erythematosus, polymyalgia rheumatica, giant cell arteritis, rheumatoid arthritis, and/or vasculitis before or during the study period (1 January 1998 to 15 March 2017). GC, glucocorticoid; PED, prednisolone equivalent dose.